Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

The study funding process came to a halt when the Trump administration announced the cancellation of roughly $400 million in ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Researchers at the University of Helsinki have found that metformin can activate certain immune cells, making them better at spotting and attacking cancer. The findings, published in the Journal for ...

A cross-sectional analysis of firearm injury-related emergency department (ED) visits found that between 2018 and 2023, there was approximately one firearm injury ED visit every 30 minutes in the 10 ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Delirium is a sudden and serious condition that causes confusion and a lack of awareness. It often happens quickly, ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.